Investors sold shares of Celgene Corp. (NASDAQ:CELG) on strength during trading hours on Wednesday. $118.43 million flowed into the stock on the tick-up and $160.71 million flowed out of the stock on the tick-down, for a money net flow of $42.28 million out of the stock. Of all equities tracked, Celgene Corp. had the 0th highest net out-flow for the day. Celgene Corp. traded up $1.93 for the day and closed at $108.11

Several equities research analysts have commented on CELG shares. Leerink Swann reaffirmed a “market perform” rating on shares of Celgene Corp. in a report on Monday, May 2nd. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corp. in a report on Wednesday, June 8th. BTIG Research reaffirmed a “buy” rating and set a $140.00 price objective on shares of Celgene Corp. in a report on Tuesday, May 24th. RBC Capital Markets reaffirmed a “buy” rating on shares of Celgene Corp. in a report on Tuesday. Finally, Jefferies Group reaffirmed a “buy” rating and set a $138.00 price objective on shares of Celgene Corp. in a report on Tuesday. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $137.29.

The stock has a market capitalization of $83.74 billion and a price-to-earnings ratio of 52.58. The stock has a 50-day moving average price of $102.11 and a 200-day moving average price of $102.92.

Celgene Corp. (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.38 by $0.06. The firm earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. During the same period in the previous year, the firm earned $1.23 EPS. The business’s revenue was up 20.9% compared to the same quarter last year. Analysts forecast that Celgene Corp. will post $5.70 EPS for the current year.

In other Celgene Corp. news, insider Robert J. Hugin sold 75,000 shares of Celgene Corp. stock in a transaction that occurred on Monday, June 20th. The stock was sold at an average price of $100.16, for a total value of $7,512,000.00. Following the sale, the insider now owns 1,122,201 shares of the company’s stock, valued at approximately $112,399,652.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Several institutional investors recently added to or reduced their stakes in CELG. Synovus Financial Corp increased its position in Celgene Corp. by 16.6% in the fourth quarter. Synovus Financial Corp now owns 8,571 shares of the biopharmaceutical company’s stock valued at $1,027,000 after buying an additional 1,222 shares in the last quarter. Genesee Valley Trust Co. increased its position in Celgene Corp. by 4.2% in the fourth quarter. Genesee Valley Trust Co. now owns 8,820 shares of the biopharmaceutical company’s stock valued at $1,056,000 after buying an additional 359 shares in the last quarter. Investment Management of Virginia LLC increased its position in Celgene Corp. by 63.0% in the fourth quarter. Investment Management of Virginia LLC now owns 9,043 shares of the biopharmaceutical company’s stock valued at $1,083,000 after buying an additional 3,495 shares in the last quarter. NBT Bank N A NY increased its position in Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock valued at $1,107,000 after buying an additional 30 shares in the last quarter. Finally, Johnson Financial Group Inc. increased its position in Celgene Corp. by 2.9% in the fourth quarter. Johnson Financial Group Inc. now owns 9,557 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 266 shares in the last quarter.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.